1-20 of 406 Search Results for

pharmaceutical prices

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Article
J Health Polit Policy Law (2022) 47 (6): 755–778.
Published: 01 December 2022
...Marc A. Rodwin Abstract This article compares the pharmaceutical pricing policies employed by public and private insurers in the United States with seven price and spending control strategies employed in the United Kingdom, France, and Germany. Differences between American and European policies...
FIGURES
Journal Article
J Health Polit Policy Law (2022) 47 (6): 629–648.
Published: 01 December 2022
...Pragya Kakani; Michael Chernew; Amitabh Chandra Abstract Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered...
FIGURES | View All (4)
Includes: Supplementary data
Journal Article
J Health Polit Policy Law (2018) 43 (1): 5–18.
Published: 01 February 2018
... taken daily for the rest of their lives, the “price per pill” would have fallen to levels that would have looked downright cheap. The current approach to financing drugs encourages pharmaceutical companies to develop drugs patients will take for the rest of their lives, rather than cures that provide...
Journal Article
J Health Polit Policy Law (2014) 39 (3): 691–705.
Published: 01 June 2014
... political and regulatory environment, this report explores pharmaceutical pricing options for Russia that balance greater access to medicines with achieving government plans of boosting local pharmaceutical production. To match innovative medicine prices with their health benefits, in the long run, we...
FIGURES
Journal Article
J Health Polit Policy Law (2003) 28 (1): 109–132.
Published: 01 February 2003
...Ramón Castellblanch A comparison of the Vermont and Maine cases of attempting to control pharmaceutical prices in the year 2000 shows that the Maine legislators were more successful in challenging pharmaceutical industry political power. This comparison shows that challenging the industry...
Journal Article
J Health Polit Policy Law (1998) 23 (2): 265–290.
Published: 01 April 1998
... a variety of published and unpublished sources, including interviews with public policy and pharmaceutical experts in each country. This article presents different approaches to encouraging the development of orphan drugs while ensuring access by regulating their prices. Additionally, the article describes...
Journal Article
J Health Polit Policy Law (2009) 34 (6): 931–977.
Published: 01 December 2009
... of the health service to the present, as they have grappled with the overlapping challenges of pharmaceutical safety, efficacy, cost-effectiveness, pricing, promotion, and advertising. The article draws on the concepts of “corporate bias” and “regulatory capture” from political theory, and “counter-vailing...
Journal Article
J Health Polit Policy Law (2014) 39 (3): 689–690.
Published: 01 June 2014
...: MSF Calls on GAVI and Pharmaceutical Companies to Extend Discounts so More Children Can Be Reached .” April 23 . www.msf.org/article/global-vaccines-community-must-cut-costs-new-vaccines . Moïse Pierre , and Docteur Elizabeth . 2007 . Pharmaceutical Pricing and Reimbursement...
Journal Article
J Health Polit Policy Law (2013) 38 (6): 1081–1102.
Published: 01 December 2013
... Insurance (INAMI/ RIZIV) Inpatient and outpatient drugs Yes Canada Canadian Agency for Drugs and Technologies in Health/Common Drug Review Outpatient drugs Yes Finland Pharmaceuticals Pricing Board Outpatient drugs Yes France Haute Autorité de Santé (HAS) Voluntary submissions...
FIGURES
Journal Article
J Health Polit Policy Law (2009) 34 (6): 979–1010.
Published: 01 December 2009
... care administrators and patients for high-quality, low-cost medicines and the objective of the innovator pharmaceutical industry to find and approve new drugs that are price protected and sell them in a way that maximizes revenues. Duke University Press 2009 Abbott, F. M. 2004 . The Doha...
Journal Article
J Health Polit Policy Law (2013) 38 (3): 573–597.
Published: 01 June 2013
... Drugs . Washington, DC : US Department of Health and Human Services . Berndt E. R. Aitken M. L. . 2010 . “Brand Loyalty, Generic Entry, and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation.” NBER Working Paper No. 16431 (October...
Journal Article
J Health Polit Policy Law (2003) 28 (4): 615–658.
Published: 01 August 2003
... of interest (Gribbin 2001; Stelfox et al. 1998). In considering the broader context of pharmaceutical policy, all four nations also differ in their approach to health insurance coverage and reg- ulation of drug prices. In Canada, Britain, and France, not only does the government regulate...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 779–796.
Published: 01 December 2022
...Richard Frank; Rena M. Conti; Jonathan Gruber Abstract International reference prices (IRP), also called external reference prices, are widely used across developed nations. IRP uses the prices paid in other countries to either inform negotiations with the pharmaceutical industry or as a cap...
Journal Article
J Health Polit Policy Law (2021) 46 (6): 1053–1068.
Published: 01 December 2021
...Rachel E. Sachs Abstract Throughout his four years in office, President Trump made prescription drug pricing a focus of his policy agenda. President Trump not only used strong language to criticize the pharmaceutical industry and its practices but also introduced ambitious reform policies that had...
Journal Article
J Health Polit Policy Law (1999) 24 (4): 653–696.
Published: 01 August 1999
... policies. It first distinguishes targets from systems of control. Targets can then be divided into categories of service (e.g., hospital care, pharmaceutical treatment) and components of cost (e.g., price and volume). Systems can be classified in terms of the degree of pooling of finance, ranging from...
Journal Article
J Health Polit Policy Law (2008) 33 (2): 225–247.
Published: 01 April 2008
... the price of maximizing health gains, subject to a budget or resource constraint. However, the underlying assumptions are implausible, particularly in the context of pharmaceutical care. Moreover, budget impact analysis is more useful to the decision maker than cost-effectiveness analysis...
Journal Article
J Health Polit Policy Law (1979) 4 (2): 155–175.
Published: 01 April 1979
... to control prices of pharmaceuticals, prior to enactment of some form of national health insurance, if successful, will call forth pharmaceutical industry strategies which could negate program benefits. Copyright © 1979 by the Dept. of Health Administration, Duke University 1979 The authors wish...
Journal Article
J Health Polit Policy Law (2022) 47 (6): 731–753.
Published: 01 December 2022
... ). Senate Finance also made insulin a major focus of hearings on pharmaceutical prices that began a week later (Senate Finance Committee 2019 ). The House Energy and Commerce Subcommittee on Hearings and Investigations held a series of hearings named “Priced Out of a Lifesaving Drug” on April 2 and 10...
FIGURES
Journal Article
J Health Polit Policy Law (2013) 38 (3): 505–544.
Published: 01 June 2013
... . Calfee John E. 2002 . “Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs.” Journal of Public Policy and Marketing 21 , no. 2 : 174 – 93 . Capella Michael L. . 2009 . “Do Pharmaceutical Marketing Activities Raise Prices? Evidence from Five Major...
Journal Article
J Health Polit Policy Law (2010) 35 (5): 705–742.
Published: 01 October 2010
... on Health . Ottawa: National Forum on Health. Neale, S., W. N. Palmer, and A. Salazar. 2003 . The Pharmaceutical Pricing, Reimbursement, and Prescribing Environment in Canada . Decision Resources. Oliver, T. R. 2000 . Commentary: Dynamics without Change: The New Generation. Journal of Health...